FI20126281L - Temotsolomidin polymeeripartikkelipohjainen annosmuoto pahanlaatuisten kasvainten hoitoon - Google Patents

Temotsolomidin polymeeripartikkelipohjainen annosmuoto pahanlaatuisten kasvainten hoitoon Download PDF

Info

Publication number
FI20126281L
FI20126281L FI20126281A FI20126281A FI20126281L FI 20126281 L FI20126281 L FI 20126281L FI 20126281 A FI20126281 A FI 20126281A FI 20126281 A FI20126281 A FI 20126281A FI 20126281 L FI20126281 L FI 20126281L
Authority
FI
Finland
Prior art keywords
temozolomide
treatment
dosage form
polymer particle
malignant neoplasms
Prior art date
Application number
FI20126281A
Other languages
English (en)
Swedish (sv)
Inventor
Ekaterina Vasilenko
Evgeny Vorontsov
Evgenij Severin
Victor Gulenko
Maxim Mitrokhin
Original Assignee
Filana Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Filana Ltd Oy filed Critical Filana Ltd Oy
Priority to FI20126281A priority Critical patent/FI20126281L/fi
Priority to EA201591111A priority patent/EA201591111A1/ru
Priority to PCT/FI2013/051151 priority patent/WO2014091078A1/en
Priority to US14/650,799 priority patent/US20150328169A1/en
Publication of FI20126281L publication Critical patent/FI20126281L/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08—Lactones or lactides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FI20126281A 2012-12-10 2012-12-10 Temotsolomidin polymeeripartikkelipohjainen annosmuoto pahanlaatuisten kasvainten hoitoon FI20126281L (fi)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FI20126281A FI20126281L (fi) 2012-12-10 2012-12-10 Temotsolomidin polymeeripartikkelipohjainen annosmuoto pahanlaatuisten kasvainten hoitoon
EA201591111A EA201591111A1 (ru) 2012-12-10 2013-12-10 Лекарственная дозированная форма, состоящая из полимерных частиц темозоломида
PCT/FI2013/051151 WO2014091078A1 (en) 2012-12-10 2013-12-10 Polymeric particles-based temozolomide dosage form
US14/650,799 US20150328169A1 (en) 2012-12-10 2013-12-10 Polymeric particles-based temozolomide dosage form

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20126281A FI20126281L (fi) 2012-12-10 2012-12-10 Temotsolomidin polymeeripartikkelipohjainen annosmuoto pahanlaatuisten kasvainten hoitoon

Publications (1)

Publication Number Publication Date
FI20126281L true FI20126281L (fi) 2014-06-11

Family

ID=50933803

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20126281A FI20126281L (fi) 2012-12-10 2012-12-10 Temotsolomidin polymeeripartikkelipohjainen annosmuoto pahanlaatuisten kasvainten hoitoon

Country Status (4)

Country Link
US (1) US20150328169A1 (fi)
EA (1) EA201591111A1 (fi)
FI (1) FI20126281L (fi)
WO (1) WO2014091078A1 (fi)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
US11890292B2 (en) 2017-02-27 2024-02-06 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2018170457A1 (en) 2017-03-17 2018-09-20 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
EP3691632A4 (en) * 2017-10-06 2021-05-26 Research Cancer Institute of America COMPOSITIONS, METHODS, SYSTEMS AND / OR KITS FOR THE PREVENTION AND / OR TREATMENT OF NEOPLASMS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5806444B2 (ja) * 2005-12-02 2015-11-10 ノバルティス アーゲー 免疫原性組成物で使用するためのナノ粒子
US10555911B2 (en) * 2012-05-04 2020-02-11 Yale University Highly penetrative nanocarriers for treatment of CNS disease
EP2662079A1 (en) * 2012-05-10 2013-11-13 Ordway Research Institute, Inc. Uses of formulations of thyroid hormone antagonists and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells

Also Published As

Publication number Publication date
EA201591111A1 (ru) 2016-04-29
US20150328169A1 (en) 2015-11-19
WO2014091078A1 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
IL288181A (en) Cancer treatment methods
HK1221646A1 (zh) 高劑量普利多匹定用於治療亨廷頓舞蹈症的用途
FI20125146A (fi) Selluloosamassan esikäsittelymenetelmä
IL241232B (en) Cancer treatment agents
EP2968348A4 (en) COMPOUNDS FOR THE TREATMENT OF CANCER
DK2717941T3 (da) Behandling af cancer
DK2861584T3 (da) Pyridopyrazin- og naphthyridinderivater til behandling af cancer
DK2785349T3 (da) Kombinationsbehandling af cancer
HK1214128A1 (zh) 癌症的治療
DK2825558T3 (da) Kombinationsterapi til behandling af ovariecancer
GB201217892D0 (en) Treatment of cancer
FI20136184L (fi) Menetelmä maidon käsittelemiseksi
DK2802351T3 (da) Midler til behandling af triple-negativ brystkræft
HK1204956A1 (en) Treatment of cancer
FI20126281L (fi) Temotsolomidin polymeeripartikkelipohjainen annosmuoto pahanlaatuisten kasvainten hoitoon
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
GB201403083D0 (en) Treatment of cancer
DK2922563T3 (da) Cd44v6-afledte peptider til behandling af metastaserende kræfttyper
HK1232118A1 (zh) 癌症的治療
IL242013B (en) Treatment of autism spectrum disorder
GB201217890D0 (en) Treatment of cancer
HK1224215A1 (zh) 高劑量普利多匹定用於治療亨廷頓舞蹈症的用途
FI20125365L (fi) Biopolttoainepellettien valmistus- ja käsittelyjärjestelmä
FI20126161L (fi) Seinän pintakäsittely
HUP1300654A2 (en) Oxidative treatment of liquids

Legal Events

Date Code Title Description
MM Patent lapsed